両親媒性ポリマーで血管内皮をコーティングし免疫反応を抑制~腎移植の長期生着率の向上につながると期待~

ad

2025-09-24 産業技術総合研究所

産業技術総合研究所(産総研)とスウェーデンのiCoat Medical社、ウプサラ大学の共同研究は、両親媒性ポリマー(PEG脂質)による血管内皮コーティング技術を開発し、ブタ腎移植実験で免疫反応を抑制できることを示した。腎移植では移植直後に「虚血再灌流障害」が起こり長期生着率を下げる要因となるが、この技術により血管内皮を保護し、免疫反応を軽減できることが確認された。さらに臨床応用に向けた最適条件も明確化され、現在ヒト腎移植での臨床試験が進行中である。成果はAmerican Journal of Transplantationに掲載された。

両親媒性ポリマーで血管内皮をコーティングし免疫反応を抑制~腎移植の長期生着率の向上につながると期待~
概要図 両親媒性ポリマー(PEG脂質)で血管内皮コーティングしたブタ腎臓の移植実験

<関連情報>

腎移植における虚血再灌流障害を軽減する新たな原理 A new principle to attenuate ischemia-reperfusion injury in kidney transplantation

Ali-Reza Biglarnia, Yuji Teramura, Sana Asif, Claudia Dührkop, Vivek Anand Manivel, Elin Manell, Patricia Hedenqvist, Anneli Rydén, Felix Sellberg, Karin Fromell, Sabine Hammer, Markus Huber-Lang, Kristina N. Ekdahl, Marianne Jensen-Waern, Bo Nilsson
American Journal of Transplantation  Available online: 24 September 2025
DOI:https://doi.org/10.1016/j.ajt.2025.08.024

Abstract

Ischemia-reperfusion injury in transplantation remains a significant clinical challenge with regard to both short-term and long-term complications. In this study, we developed a new amphiphilic construct, polyethylene glycol (PEG)-conjugated lipids (PEG-LIPIDs), to be administered ex vivo intra-arterially to procured porcine kidney allografts before reperfusion. The aim was to create a protective cell membrane barrier, preventing the recognition of ligands exposed on renal cells by plasma proteins and cells of the intravascular innate immune system. In vitro cell studies confirmed the safety of PEG-LIPID with no observed toxicity and demonstrated its efficacy in masking ligands on various cell types. The PEG-LIPID was evaluated in 3 porcine allogeneic transplant models: 1 acute dual en bloc nonsurvival transplant model (duration 6 hours) and 2 survival models with low and high ischemic stress, respectively (duration 96 hours). No immunosuppression was employed. Across all 3 porcine transplant models, PEG-LIPID consistently mitigated ischemia-reperfusion-induced thromboinflammation (complement, coagulation, and kallikrein/kinin activation) and long-term inflammation with a marked reduction in cytokine responses, including lower levels of interleukin 6. The PEG-LIPID-treated kidneys exhibited significantly improved allograft function, reflected in robustly lower creatinine levels. This translational study confirmed that the PIG-LIPID is a strong candidate drug to mitigate ischemia-reperfusion injury in clinical kidney transplantation.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました